May be a ridiculous question on my part, but given a few studies out now with a similar sponsor/aim, what are the implications of any attempt to "piggyback" the potential success of our injectable PPS studies with oral PPS (being aware bioavailability is an issue with oral).
research reports and media, page-3737
-
- There are more pages in this discussion • 676 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.0¢ |
Change
-0.005(2.13%) |
Mkt cap ! $80.45M | |||
| Open | High | Low | Value | Volume |
| 23.5¢ | 24.0¢ | 23.0¢ | $63.43K | 270.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 213534 | 23.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.5¢ | 76890 | 2 |
View Market Depth
| Last trade - 16.10pm 05/09/2024 (20 minute delay) ? |
| PAR (ASX) Chart |